RE:RE:RE:Conditions are right for biopharma M&A to break outRepeat: June 08, 2023 - "Big Pharma Goes Shopping: Biotech Acquisitions Set to Skyrocket"
' When it comes to biotech M&A activity, cancer has been one of the hottest areas of focus. This is due in part to the significant progress that has been made in the development of cancer treatments in recent years. With new treatments showing promise in clinical trials and the potential for significant profits in the market, larger companies are looking to acquire young biotechs in the space.'
'Overall, it seems that 2023 will be an exciting year for the biotech industry, with continued M&A activity expected. For retail investors looking to get in on the action, investing in smallcap biotech companies with some wins under their belt could be a smart strategy, provided that they do their due diligence and [had taken] a long-term view. '
https://ca.sports.yahoo.com/news/big-pharma-goes-shopping-biotech-145100817.html